S-1: a promising new oral fluoropyrimidine derivative
The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Abstract
The fluoropyrimidine anticancer agent 5-fluorouracil (5-FU) is active in a wide range of solid tumors, particularly gastric, colorectal, and head and neck cancers. Whilst infusional 5-FU is associated with higher response rates and a favorable safety profile compared with the classical i.v. bolus administration, prolonged infusions can be inconvenient for the patients, and catheter-related problems are common complications. An oral 5-FU formulation would allow for sustained 5-FU plasma concentrations, mimicking the pharmacokinetics (PK) of a continuous infusion with the addition of convenience of administration. The oral administration of 5-FU itself is not feasible owing to the high activity of dihydropyrimidine dehydrogenase (DPD) in the gut wall, which causes rapid metabolism of the drug and results in decreased and erratic absorption of 5-FU and nonlinear PK. To bypass this problem, oral fluoropyrimidine derivatives were developed either in the form of 5-FU prodrugs (i.e., tegafur, doxifluridine or capecitabine), or as enzyme inhibitors (i.e., eniluracil) administered with 5-FU, or as both prodrugs and enzyme inhibitors (i.e., S-1, UFT or BOF-A2). This review focuses on the oral fluoropyrimidine S-1, which consists of the 5-FU prodrug tegafur (ftorafur, FT) and two enzyme inhibitors, CDHP (5-chloro-2,4-dihydroxypyridine) and OXO (potassium oxonate), in a molar ratio of 1(FT):0.4 (CDHP):1(OXO). Phase II trials have demonstrated that S-1, as a single agent, is active for the treatment of gastric, colorectal, head and neck, breast, non-small cell lung, and pancreatic cancers. Phase III trials are currently underway in gastric cancer and these results are awaited to confirm the Phase II findings. Furthermore, the combination of S-1 with cisplatin (CDDP), irinotecan or docetaxel for the treatment of gastric cancer and with CDDP for non-small cell and pancreatic cancer is feasible and active. The activity observed with S-1 in the Phase II studies is at least equivalent to, if not better than, continuous i.v. and bolus 5-FU and the other oral fluoropyrimidines. Thus, we may finally be seeing the realization of oral treatments for the management of various solid tumors and could be on the brink of a new approach to treatment strategies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The vast majority of 5-FU is catabolized into inactive metabolites by dihydropyrimidine dehydrogenase (DPD) in the liver [97].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [97]
Citations
Cites
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A., Furukawa, H., Nakajima, T., Ohashi, Y., Imamura, H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072252 · Cited by 2,517
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926 · cited 2×
“2 months was reported for docetaxel/CDDP/5-FU (DCF) by the V325 Study Group [104] ; 10.”
BackgroundInfluentialKoizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70035-4 · Cited by 1,847 · cited 2×
“Interestingly, it seems that the difference in dosage of S-1 might be attributed to the higher activity of cytochrome P-450 2A6 enzyme – which catalyzes the conversion of tegafur to 5-FU – in white than in Japanese people as well as larger body surface area in North American people, leading to higher serum concentrati…”
BackgroundFluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603 · cited 1×
“[2] reported 5-fluorouracil (5-FU) in 1957, pharmacokinetic and biochemical studies of 5-FU have been widely conducted to examine different means of reinforcing its efficacy and its regimen [3] .”
Background(2012) · Hepatogastroenterology · doi:10.5754/hge11893 · Cited by 1,338
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.301 · Cited by 981
Skipper, H. E., Schabel, F. M., & Wilcox, W. S. (1964) · PubMed · Cited by 904
Fluorouracil: biochemistry and pharmacology.
Pinedo, H. M., & Peters, G. F. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.10.1653 · Cited by 834 · cited 1×
“[2] reported 5-fluorouracil (5-FU) in 1957, pharmacokinetic and biochemical studies of 5-FU have been widely conducted to examine different means of reinforcing its efficacy and its regimen [3] .”
BackgroundLokich, J. J., Ahlgren, J. D., Gullo, J. J., Philips, J. A., & Fryer, J. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.425 · Cited by 773 · cited 1×
“The use of continuous infusion of 5-FU using portable infusion pumps allowed prolonged cell exposure to the drug and abolished the problem with its low half-life (5 – 20 min) and resulted in higher clinical activity [6-9] .”
BackgroundSakata, Y., Ohtsu, A., Horikoshi, N., Sugimachi, K., Mitachi, Y., & Taguchi, T. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00211-1 · Cited by 565
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3537 · Cited by 495
Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer
Koizumi, W., Kurihara, M., Nakano, S., & Hasegawa, K. (2000) · Oncology · doi:10.1159/000012099 · Cited by 440
Seifert, P., Baker, L. H., Reed, M. L., & Vaitkevicius, V. K. (1975) · Cancer · doi:10.1002/1097-0142(197507)36:1<123::aid-cncr2820360108>3.0.co;2-c · Cited by 420 · cited 1×
“The use of continuous infusion of 5-FU using portable infusion pumps allowed prolonged cell exposure to the drug and abolished the problem with its low half-life (5 – 20 min) and resulted in higher clinical activity [6-9] .”
BackgroundShirasaka, T., Nakano, K., Takechi, T., Satake, H., Uchida, J., Fujioka, A., Saitô, H., Okabe, H., Oyama, K., Takeda, S., et al. (1996) · PubMed · Cited by 370
Shirasaka, T., Shimamoto, Y., & Fukushima, M. (1993) · PubMed · Cited by 348
Beck, A., Etienne, M. C., Chéradame, S., Fischel, J. L., Formento, P., Renée, N., & Milano, G. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00216-r · Cited by 270 · cited 1×
“Furthermore, DPD activity varies up to 100-fold, depending on the particular cancer cells, and it might be one of the main factors that affect the sensitivity of tumors to 5-FU [14] .”
BackgroundTatsumi, K., Fukushima, M., Shirasaka, T., & Fujii, S. (1987) · PubMed · Cited by 260
Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion.
Rj, F., Baker, L. H., Buroker, T. R., Horwitz, J. P., & Vaitkevicius, V. K. (1980) · PubMed · Cited by 234
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Hirata, K., Horikoshi, N., Aiba, K., Okazaki, M., DENNO, R., Sasaki, K., Nakano, Y., Ishizuka, H., Yamada, Y., Uno, S., et al. (1999) · PubMed · Cited by 226
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
Kawahara, M., Furuse, K., Segawa, Y., Yoshimori, K., Matsui, K., Kudoh, S., Hasegawa, K., & Niitani, H. (2001) · British Journal of Cancer · doi:10.1038/sj.bjc.6692031 · Cited by 220
Pazdur, R., Lassere, Y., Rhodes, V, Ajani, J. A., Sugarman, S. M., Patt, Y. Z., Jones, D. V., Markowitz, A. B., Abbruzzese, J. L., & Bready, B. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2296 · Cited by 205 · cited 8×
“Many trials with S-1 in CRC are underway: Phase II study in advanced CRC patients with S-1 plus CPT-11 (IRIS); Phase I/II (SOL) study with S-1 plus leucovorin and oxaliplatin for untreated metastatic CRC; Phase I trial with S-1, oxaliplatin, CPT-11 (IRIS+Bev); Phase II trials with S-1 and bevacizumab in elderly patien…”
BackgroundInfluentialOhtsu, A., Baba, H., Sakata, Y., Mitachi, Y., Horikoshi, N., Sugimachi, K., & Taguchi, T. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1236 · Cited by 204
Fujii, S., Ikenaka, K., Fukushima, M., & Shirasaka, T. (1978) · PubMed · Cited by 184
Phase I Pharmacokinetic Study of S-1 Plus Cisplatin in Patients With Advanced Gastric Carcinoma
Ajani, J. A., Faust, J., Ikeda, K., Yao, J. C., Anbe, H., Carr, K. L., Houghton, M., & Urrea, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.917 · Cited by 182 · cited 1×
“trial [107] in the USA, where the administered dose was 25 mg/m 2 twice daily.”
BackgroundMattison, L. K., Fourie, J., Desmond, R. A., Modak, A., Saif, M. W., & Diasio, R. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0747 · Cited by 174 · cited 1×
“DPD deficiency also differs pharmacogenomically among several racial groups; African-Americans do have a lower level of mean DPD activity and a threefold higher incidence of DPD deficiency, which explains the decreased toxicity (diarrhea, nausea, stomatitis) in African-Americans compared with Caucasians; while among A…”
ResultSelf-citationSugimachi, K., Maehara, Y., Horikoshi, N., Shimada, Y., Sakata, Y., Mitachi, Y., & Taguchi, T. (1999) · Oncology · doi:10.1159/000012032 · Cited by 171
A late phase II study of S-1 for metastatic pancreatic cancer
Okusaka, T., Funakoshi, A., Furuse, J., Boku, N., Yamao, K., Ohkawa, S., & Saito, H. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0514-8 · Cited by 169 · cited 3×
“, 2002, 2003 [58,59] Pancreatic cancer – –”
Background松本, 篤., & 浜本, 康. (2008) · Mebio oncology · Cited by 158
Phase I Clinical and Pharmacokinetic Study of Oral S-1 in Patients With Advanced Solid Tumors
van Groeningen, C. J., Peters, G. J., Schornagel, J. H., Gall, H. E., Noordhuis, P., de Vries, M., Turner, S., Swart, M., Pinedo, H. M., Hanauske, A.-R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2772 · Cited by 155 · cited 1×
“In the dose of 45 mg/m 2 , grade 3 and 4 diarrhea was observed; the investigators recommended the dose of 40 mg/m 2 only for the chemo-naive patients with GI solid tumors [44] .”
BackgroundShirasaka, T., Shimamoto, Y., Ohshimo, H., Saito, H., & Fukushima, M. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685830 · Cited by 151 · cited 1×
“It is known that CDDP has both direct activity of inhibiting the DNA synthesis through direct binding to DNA and indirect activity of functioning as a modulator of 5-FU [83-85] .”
BackgroundPhase II study of S-1 in patients with advanced biliary tract cancer
Ueno, H., Okusaka, T., Ikeda, M., Takezako, Y., & Morizane, C. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602208 · Cited by 149 · cited 1×
“[61] , 19 patients with advanced biliary tract cancer and no history of previous radiotherapy or chemotherapy received S-1 orally.”
BackgroundMcCollum, A. D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.15.1160 · Cited by 146 · cited 1×
“DPD deficiency also differs pharmacogenomically among several racial groups; African-Americans do have a lower level of mean DPD activity and a threefold higher incidence of DPD deficiency, which explains the decreased toxicity (diarrhea, nausea, stomatitis) in African-Americans compared with Caucasians; while among A…”
ResultHoughton, J. A., Houghton, P. J., & Wooten, R. S. (1979) · PubMed · Cited by 142
The Prodrugs of 5-Fluorouracil
Malet‐Martino, M., Jolimaître, P., & Martino, R. (2002) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011023354146 · Cited by 128
An Early Phase II Study of S-1 in Patients with Metastatic Pancreatic Cancer
Ueno, H., Okusaka, T., Ikeda, M., Takezako, Y., & Morizane, C. (2005) · Oncology · doi:10.1159/000086771 · Cited by 120 · cited 1×
“Clinical trials with single-agent S-1 in solid tumors and their main adverse events [49-59] .”
Backgroundffski, P. S. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200402000-00001 · Cited by 114
The oral fluoropyrimidines in cancer chemotherapy.
Lamont, E. B., & Schilsky, R. L. (1999) · PubMed · Cited by 113
Scanlon, K. J., Safirstein, R. L., Thies, H. L., Gross, R. B., Waxman, S., & Guttenplan, J. B. (1983) · PubMed · Cited by 111
[Late phase II study of S-1 in patients with advanced head and neck cancer].
Inuyama, Y., Kida, A., Tsukuda, M., Kohno, N., & Satake, B. (2001) · PubMed · Cited by 106
Chollet, P. J. M., Schöffski, P., Weigang-Köhler, K., Schellens, J. H. M., Curé, H., Pavlidis, N. A., Grünwald, V., Boer, R. D., Wanders, J., & Fumoleau, P. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00237-5 · Cited by 105 · cited 1×
“[77] , S-1 was given orally twice daily at 40 mg/m 2 in non-pretreated patients with metastatic or locally advanced, unresectable gastric cancer.”
MethodFukushima, M., Satake, H., Uchida, J., Shimamoto, Y., Kato, T., Takechi, T., Okabe, H., Fujioka, A., Nakano, K., Ohshimo, H., et al. (1998) · International Journal of Oncology · doi:10.3892/ijo.13.4.693 · Cited by 105
S-1 in gastric cancer: a comprehensive review
Maehara, Y. (2003) · Gastric Cancer · doi:10.1007/s10120-003-0232-9 · Cited by 102
Hoff, P. M., Saad, E. D., Ajani, J. A., Lassere, Y., Wenske, C., Medgyesy, D. C., Dwivedy, S., Russo, M., & Pazdur, R. (2003) · PubMed · Cited by 94
Kang, Y., Kang, W. K., Shin, D. B., Chen, J., Xiong, J., Wang, J., Lichinitser, M., Philco, M., Suarez, T., & Santamaria, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.lba4018 · Cited by 90
Yamada, Y., Hamaguchi, T., Goto, M., Muro, K., Matsumura, Y., Shimada, Y., Shirao, K., & Nagayama, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601224 · Cited by 83
den Brande, J. V., Schöffski, P., Schellens, J. H. M., Roth, A., Duffaud, F., Weigang-Köhler, K., Reinke, F., Wanders, J., de Boer, R. F., Vermorken, J. B., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600781 · Cited by 76 · cited 1×
“In the European study performed by the Early Clinical Studies Group (EORTC) in 2003 [64] , the dose of S-1 was finally reduced to 35 mg/m 2 (daily for 28 days, repeated every 5 weeks) owing to unexpected severe toxicity (diarrhea), although 24 and 46% of the chemo-naive patients with advanced/metastatic CRC experience…”
MethodNishiyama, M., Yamamoto, W., Park, J. S., Okamoto, R., Hanaoka, H., Takano, H., Saito, N., Matsukawa, M., Shirasaka, T., & Kurihara, M. (1999) · PubMed · Cited by 74
Kouwaki, M., Hamajima, N., Sumi, S., Nonaka, M., Sasaki, M., Dobashi, K., Kidouchi, K., Togari, H., & Wada, Y. (1998) · PubMed · Cited by 74
Papamichael, D. (2000) · STEM CELLS · doi:10.1634/stemcells.18-3-166 · Cited by 73 · cited 2×
“Intrapatient variability in plasma levels may be associated with the circadian rhythm of DPD activity throughout the day, influencing the catabolism of 5-FU, while the variability in plasma levels may mainly be due to the poor absorption related to the high activity of DPD in the gut wall and the liver, leading to rap…”
BackgroundMethodJapanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer
Nagashima, F., Ohtsu, A., Yoshida, S., & Ito, K. (2005) · Gastric Cancer · doi:10.1007/s10120-004-0306-3 · Cited by 69 · cited 1×
“reported the postmarketing survey of S-1 in Japanese patients, in which the authors reported the relationship between toxicity and creatinine clearance, and lower creatinine clearance related to high toxicity [113] .”
BackgroundYamaguchi, K., Aral, Y., Kanda, Y., & Akagi, K. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01100.x · Cited by 63 · cited 1×
“[112] studied the mutations of DPD gene among a Japanese population in relation to toxicity to 5-FU; one patient was found to be DPD deficient with an incidence of 0.”
BackgroundComparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil.
Toide, H., Akiyoshi, H., Minato, Y., Okuda, H., & Fujii, S. (1977) · PubMed · Cited by 60
Biochemical and clinical pharmacology of 5-fluorouracil.
Schilsky, R. L. (1998) · PubMed · Cited by 60
lyer, L., & Ratain, M. J. (1999) · Cancer Investigation · doi:10.3109/07357909909032859 · Cited by 54 · cited 1×
“The use of continuous infusion of 5-FU using portable infusion pumps allowed prolonged cell exposure to the drug and abolished the problem with its low half-life (5 – 20 min) and resulted in higher clinical activity [6-9] .”
Background[Phase I study of S-1. S-1 Study Group].
Taguchi, T., Inuyama, Y., Kanamaru, R., Hasegawa, K., Akazawa, S., Niitani, H., FURUE, H., Kurihara, M., Ota, K., Suga, S., et al. (1997) · PubMed · Cited by 52
Shirasaka, T., Yamamitsu, S., Tsuji, A., & Taguchi, T. (2000) · Investigational New Drugs · doi:10.1023/a:1006476730671 · Cited by 50 · cited 12×
“S-1 Anticancer activity and adverse reactions of S-1, FT and UFT were compared using a colon cancer implantation model in rats [19,34] .”
BackgroundMethodInfluentialIkeda, M., Furukawa, H., Imamura, H., SHIMIZU, J., Ishida, H., Masutani, S., Tatsuta, M., KAWASAKI, T., & SATOMI, T. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0457-z · Cited by 47 · cited 1×
“[48] , it has become clear that after oral administration of S-1 in comparison with continuous i.”
BackgroundPapamichael, D. (1999) · The Oncologist · doi:10.1634/theoncologist.4-6-478 · Cited by 42
Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer
Baba, H., Yamamoto, M., Endo, K., Ikeda, Y., Toh, Y., Kohnoe, S., & Okamura, T. (2003) · Gastric Cancer · doi:10.1007/s10120-003-0222-y · Cited by 41
Kimura, Y., Kikkawa, N., Iijima, S., Kato, T., Naoi, Y., Hayashi, T., Tanigawa, T., Yamamoto, H., & Kurokawa, E. (2003) · Gastric Cancer · doi:10.1007/s10120-003-0230-y · Cited by 38 · cited 1×
“Drugs (2009) 18(3) 341 decreased in the groups of patients who had already received prior therapies [73-76] .”
BackgroundMiyamoto, S., Boku, N., Ohtsu, A., Yoshida, S., Ochiai, A., Okabe, H., & Fukushima, M. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.4.653 · Cited by 37 · cited 2×
“4 and 61%, while S-1 was dosed to 40 mg/m 2 twice daily [69-72] .”
BackgroundResultOral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination
Osugi, H., Takada, N., Takemura, M., Kaseno, S., Lee, S., Ueno, M., Tanaka, Y., Fukuhara, K., Fujiwara, Y., & Kinoshita, H. (2002) · Oncology Reports · doi:10.3892/or.9.4.811 · Cited by 36 · cited 1×
“4 and 61%, while S-1 was dosed to 40 mg/m 2 twice daily [69-72] .”
BackgroundMizutani, Y., Yoshida, O., & Bonavida, B. (1998) · The Journal of Urology · doi:10.1016/s0022-5347(01)62959-8 · Cited by 33 · cited 1×
“Additionally, since 1991, there have been reports on the theory and practice of low-dose CDDP and 5-FU therapy consisting in continuous venous infusion of 5-FU and low-dose CDDP; this therapeutic modality provides response rates as high as 40 – 60% or higher than those of pre-existing therapies in patients with gastro…”
BackgroundEarly phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer
Furuse, K., Kawahara, M., Hasegawa, K., Kudoh, S., Takada, M., Sugiura, T., Ichinose, Y., Fukuoka, M., Ohashi, Y., Niitani, H., et al. (2001) · International Journal of Clinical Oncology · doi:10.1007/pl00012111 · Cited by 32
Kato, T., Shimamoto, Y., Uchida, J., Ohshimo, H., Abe, M., Shirasaka, T., & Fukushima, M. (2001) · PubMed · Cited by 32
Mori, T., Fujiwara, Y., Yano, M., Tamura, S., Yasuda, T., Takiguchi, S., & Monden, M. (2003) · Oncology · doi:10.1159/000067774 · Cited by 30 · cited 1×
“Additionally, S-1 significantly inhibited tumor growth in nude rats and mice implanted with human stomach, head and neck, and breast cancer cell lines in comparison with other oral fluoropyrimidines [37-39] .”
BackgroundNew options for outpatient chemotherapy – the role of oral fluoropyrimidines
Cunningham, D., & Coleman, R. E. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2001.0229 · Cited by 30 · cited 1×
“1 Efforts to improve effi cacy and safety of 5-FU Over the years, several schedule modifications and biomodulations have been introduced by investigators in efforts to improve the efficacy and tolerability of 5-FU [5] .”
BackgroundInuyama, Y., Kida, A., Tsukuda, M., Kohno, N., & Satake, B. (1998) · PubMed · Cited by 28
Novel anticancer drugs in Japan
Ogawa, M. (1999) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050255 · Cited by 27 · cited 1×
“OXO localizes in the gastrointestinal mucosal tract and selectively inhibits the enzyme orotate phosphoribosyl transferace (OPRT), which inhibits 5-FU phosphorylation to FUMP, which in turn limits gastrointestinal toxicity (diarrhea, nausea and vomiting) ( Figure 3 ) [30,31-33] .”
BackgroundKochi, M., Fujii, M., Kanamori, N., Kaiga, T., Aizaki, K., Takahashi, T., & Takayama, T. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0415-x · Cited by 26 · cited 1×
“The pharmacokinetics of the fluorouracil that is derived from S-1 is not influenced by the surgical procedure of gastrectomy [81] , and for this reason S-1 was suitable for the postoperative adjuvant setting.”
BackgroundYoshisue, K., Hironaga, K., Yamaguchi, S., Yamamoto, A., Nagayama, S., & KAWAGUCHI, Y. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000123 · Cited by 26 · cited 1×
“Additionally, S-1 significantly inhibited tumor growth in nude rats and mice implanted with human stomach, head and neck, and breast cancer cell lines in comparison with other oral fluoropyrimidines [37-39] .”
BackgroundMizutani, Y., Wu, X., Yoshida, O., Shirasaka, T., & Bonavida, B. (1999) · Oncology Reports · doi:10.3892/or.6.5.979 · Cited by 26 · cited 1×
“Additionally, since 1991, there have been reports on the theory and practice of low-dose CDDP and 5-FU therapy consisting in continuous venous infusion of 5-FU and low-dose CDDP; this therapeutic modality provides response rates as high as 40 – 60% or higher than those of pre-existing therapies in patients with gastro…”
BackgroundAraki, H., Fukushima, M., Kamiyama, Y., & Shirasaka, T. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00583-8 · Cited by 24 · cited 1×
“Drugs (2009) 18(3) 339 indicating promise for further future evaluation in clinical studies [41] .”
BackgroundS-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects
Takahashi, I., Kakeji, Y., Emi, Y., Sakurai, M., Yonemura, Y., Kimura, Y., & Maehara, Y. (2003) · Gastric Cancer · doi:10.1007/s10120-003-0228-5 · Cited by 21 · cited 1×
“Drugs (2009) 18(3) 341 decreased in the groups of patients who had already received prior therapies [73-76] .”
BackgroundCao, S., Lu, K., Tóth, K., Slocum, H. K., Shirasaka, T., & Rustum, Y. M. (1999) · PubMed · Cited by 20
Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer
Tsujitani, S., Fukuda, K., & Kaibara, N. (2003) · Gastric Cancer · doi:10.1007/s10120-003-0223-x · Cited by 19 · cited 2×
“Clinical trials with S-1 in combination with CDDP, CPT-11 or Docetaxel for the treatment of gastric cancer [89-101,105] .”
BackgroundHigh response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1
Hayashi, K., Imaizumi, T., Uchida, K., Kuramochi, H., & Takasaki, K. (2002) · Oncology Reports · doi:10.3892/or.9.6.1355 · Cited by 18 · cited 1×
“[60] administered S-1 (40 mg/m 2 ) alone or in combination with cisplatin (30 mg/m 2 ) on days 1 and 8, every 28 and 21 days, respectively, again with a rest of 2 weeks.”
MethodKinoshita, T., Nakajima, T., & Ohashi, Y. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4021 · Cited by 18
Biochemical Basis for Circadian‐Dependent Metabolism of Fluoropyrimidinesa
Daher, G. C., Harris, B., Willard, E. M., & Diasio, R. B. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb27255.x · Cited by 17 · cited 1×
“Intrapatient variability in plasma levels may be associated with the circadian rhythm of DPD activity throughout the day, influencing the catabolism of 5-FU, while the variability in plasma levels may mainly be due to the poor absorption related to the high activity of DPD in the gut wall and the liver, leading to rap…”
BackgroundTaguchi, T., Morimoto, K., Horikoshi, N., Takashima, S., Toge, T., Kimura, M., Sano, M., Aoyama, H., Ota, J., & Noguchi, S. (1998) · PubMed · Cited by 17
Neoadjuvant chemotherapy with S-1 for scirrhous gastric cancer: a pilot study
Kinoshitá, T., Konishi, M., Nakagohri, T., Inoue, K., Oda, T., Takahashi, S., Boku, N., Ohtsu, A., & Yoshida, S. (2003) · Gastric Cancer · doi:10.1007/s10120-003-0220-0 · Cited by 16 · cited 1×
“[78] , despite the small number of patients (5) with potentially resectable scirrhous gastric cancer, response rate of about 60% (3/5 patients) was observed after two cycles of therapy.”
BackgroundShirasaka, T., & Taguchi, T. (2006) · PubMed · Cited by 12
Changes in folate concentration in Yoshida sarcoma after administration of leucovorin or cisplatin
Omura, K., Misaki, T., Hashimoto, T., Kanehira, E., Watanabe, T., Ishida, F., Watanabe, Y., & Shirasaka, T. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686545 · Cited by 12 · cited 1×
“It is known that CDDP has both direct activity of inhibiting the DNA synthesis through direct binding to DNA and indirect activity of functioning as a modulator of 5-FU [83-85] .”
BackgroundRino, Y., Takanashi, Y., Yukawa, N., Saeki, H., Wada, H., Kanari, M., Yamada, R., Satoh, T., Yamamoto, N., & Imada, T. (2006) · PubMed · Cited by 12
Inter-ethnic variability of S-1 pharmacokinetics (PK) and correlation with CYP2A6 phenotyping
Goh, B. C., Soo, R. A., Lim, S. G., Zhang, J., Furuie, T., Urrea, P. D., & Rosen, L. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2507 · Cited by 11 · cited 1×
“carried out a study to compare S-1 PK and CYP2A6 activity of Asian patients enrolled in Singapore and Caucasian patients in the USA with advanced solid tumors [114] .”
BackgroundLongterm control of advanced and recurrent gastric cancer (ARGC) by S-1
Cho, H., Konishi, K., Tsuburaya, A., Kobayashi, O., Sairenji, M., Motohashi, H., & Imada, T. (2003) · Gastric Cancer · doi:10.1007/s10120-003-0217-8 · Cited by 10 · cited 1×
“Drugs (2009) 18(3) 341 decreased in the groups of patients who had already received prior therapies [73-76] .”
BackgroundBenson, A. B. (1998) · PubMed · Cited by 9
Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding.
Fujitani, K., Tsujinaka, T., & Hirao, M. (2003) · PubMed · Cited by 8
Shirasaka, T., Aiba, K., Araki, H., Suzuki, M., Terashima, M., & Mikami, Y. (1999) · PubMed · Cited by 6
憲男, 釆., Harima, K., Daidai, Y., Fujihara, H., & Fujii, S. (1971) · PubMed · Cited by 6
[Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Shirasaka, T., Yamamitsu, S., Tsuji, A., Terashima, M., & Hirata, K. (2000) · PubMed · Cited by 5
Unemi, N., Harima, K., Daidai, Y., Fujihara, H., & Fujii, S. (1971) · PubMed · Cited by 5
Saif, M. W., Seller, S., & Diasio, R. B. (2008) · PubMed · Cited by 4
Self-citation[A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer].
Kamata, T., Hayashi, Y., Minatoya, G., Michiwa, Y., Onishi, I., Takeda, T., KOYASAKI, N., & Kanno, M. (2001) · PubMed · Cited by 4
[A new therapeutic approach to advanced and recurrent gastric cancer by TS-1].
Yoshida, K., Nishimoto, N., Kagawa, Y., Hihara, J., Inoue, H., Kim, R., Hirai, T., Nishiyama, M., & Toge, T. (2001) · PubMed · Cited by 3
Inaba, Y., Watabe, S., Ohe, S., Kamio, Y., Koyama, M., Hayashi, K.-I., & Chiba, M. (2002) · PubMed · Cited by 3
Uehara, M., Takahashi, S., Takenaka, A., Izumi, H., Fujii, K., Ikawa, O., Miyata, K., Iizuka, R., Matsumura, H., Kakihara, N., et al. (2001) · PubMed · Cited by 2
Tsuji, A., Morita, S., Horimi, T., Takasaki, M., Takahashi, I., & Shirasaka, T. (1999) · PubMed · Cited by 2
[5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota, T. (2001) · PubMed · Cited by 2
[Clinical study of TS-1 therapy for inoperable and recurrent gastric cancer].
Moriwaki, T., Hyodo, I., Nishina, T., Kajiwara, T., Tsuzuki, T., Hirao, K., Nakauchi, M., Nasu, J., Hirasaki, S., Endo, H., et al. (2003) · PubMed · Cited by 1
Research works printed but not linked: 59
- Kubota, 2001, Gan To Kagaku Ryoho, 28, 433
- Benson, 1998, Oncology (Williston Park), 12, 28
- Houghton, 1979, Cancer Res, 39, 2406
- Unemi, 1971, Gan No Rinsho, 17, 731
- Lamont, 1999, Clin Cancer Res, 5, 2289
- Skipper, 1964, Cancer Chemother Rep, 35, 1
- Fraile, 1980, Cancer Res, 40, 2223
- Schilsky, 1998, Oncology (Williston Park), 12, 13
- Toide, 1977, Gann, 68, 553
- Fujii, 1978, Gann, 69, 763
- Shirasaka, 2000, Gan To Kagaku Ryoho, 27, 832
- Tatsumi, 1987, Jpn J Cancer Res, 78, 748
- Shirasaka, 2006, Gan To Kagaku Ryoho, 33, 4
- Shirasaka, 1993, Cancer Res, 53, 4004
- Kato, 2001, Anticancer Res, 21, 1705
- Cao, 1999, Clin Cancer Res, 5, 267
- Shirasaka, 1996, Cancer Res, 56, 2602
- Shirasaka, 1993, Proc Int Congr Chemother, 18, 927
- Fukushima, 1998, Int J Oncol, 13, 693
- Shirasaka, 1998, Gan To Kagaku Ryoho, 25, 371
- Taguchi, 1997, Gan To Kagaku Ryoho, 24, 2253
- Hirata, 1999, Clin Cancer Res, 5, 2000
- Hoff, 1999, Proc Am Soc Clin Oncol, 18, 665
- Hoff, 2003, Clin Cancer Res, 9, 134
- Tagishi, 1996, Proc Am Soc Clin Oncol, 15, 151
- Taguchi, 1998, Gan To Kagaku Ryoho, 25, 1035
- Sano, 2000, Proc Am Soc Clin Oncol, 19, 404
- 10.1054/bjoc.2001.2031 · doi:10.1054/bjoc.2001.2031 · Paper page
- Fujii, 1996, Proc Am Soc Clin Oncol, 15, 894
- Inuyama, 1998, Gan To Kagaku Ryoho, 25, 1151
- Inuyama, 2001, Gan To Kagaku Ryoho, 28, 1381
- Okada, 2002, Proc Am Soc Clin Oncol, 21, 171a
- Hayashi, 2002, Oncol Rep, 9, 1355
- Sawada, 2002, Proc Am Soc Clin Oncol, 21, 102b
- Horikoshi, 1996, Proc Am Soc Clin Oncol, 15, 466
- Miyamoto, 2000, Int J Oncol, 17, 653
- Yoshida, 2001, Gan To Kagaku Ryoho, 28, 1403
- Inaba, 2002, Gan To Kagaku Ryoho, 29, 239
- Osugi, 2002, Oncol Rep, 9, 811
- Moriwaki, 2003, Gan To Kagaku Ryoho, 30, 489
- Fujitani, 2003, Hepato-gastroenterology, 50, 889
- Kinoshita, 2005, Prog Proc Am Soc Clin Oncol, 23, 313
- Scanlon, 1983, Cancer Res, 43, 4211
- Shirasaka, 1999, Gan To Kagaku Ryoho, 26, 456
- Mizutani, 1999, Oncol Rep, 6, 979
- Nishiyama, 1999, Clin Cancer Res, 5, 2620
- Tsuji, 1999, Gan To Kagaku Ryoho, 26, 326
- Ohtsu, 2001, Proc Am Soc Clin Oncol, 20, 165a
- Kamata, 2001, Gan To Kagaku Ryoho, 28, 1419
- Tsujitani, 2003, Proc Am Soc Clin Oncol, 22, 1358
- Narahara, 2002, Proc Am Soc Clin Oncol, 21, 170a
- Komatsu, 2002, Proc Am Soc Clin Oncol, 21, 171a
- Yamashita, 2003, Proc Am Soc Clin Oncol, 22, 1428
- Yamada, 2003, Proc Am Soc Clin Oncol, 22, 1314
- Komatsu, 2003, Proc Am Soc Clin Oncol, 22, 1282
- Rino, 2006, Anticancer Res, 26, 1455
- Yoshida, 2003, Proc Am Soc Clin Oncol, 22, 1292
- Saif, 2008, JOP, 9, 226
- Kouwaki, 1998, Clin Cancer Res, 4, 2999
Cited by
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Ueno, H., Ioka, T., Ikeda, M., Ohkawa, S., Yanagimoto, H., Boku, N., Fukutomi, A., Sugimori, K., Baba, H., Yamao, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3680 · Cited by 628
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H.-J., & Ladner, R. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.51 · Cited by 388
5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
Miura, K., Kinouchi, M., Ishida, K., Fujibuchi, W., Naitoh, T., Ogawa, H., Ando, T., Yazaki, N., Watanabe, K., Haneda, S., et al. (2010) · Cancers · doi:10.3390/cancers2031717 · Cited by 260
“It has been demonstrated that 80% to 85% of 5-FU is catabolized to inactive metabolites by dihydropyrimidine dehydrogenase (DPD), and only 1 to 3% of the original dose of 5-FU mediates the cytotoxic effects on tumor cells and normal tissues through anabolic actions [6], thereby inhibiting DNA synthesis and RNA process…”
BackgroundOhtake, Y., Sato, T., Kobayashi, T., Nishimoto, M., Taka, N., Takano, K., Yamamoto, K., Ohmori, M., Yamaguchi, M., Takami, K., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300884k · Cited by 174
Metadata
- Authors
- Saif, M. W., Syrigos, K. N., & Katirtzoglou, N. A.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Yale University (US)
- ORCID
- Saif, Muhammad Wasif
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2009-03
- Volume
- 18
- Issue
- 3
- Pages
- 335-348
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2168388707
- Cited by
- 101
- References
- 100
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 10 · 2023: 1 · 2022: 7 · 2021: 7 · 2020: 3 · 2019: 7 · 2018: 1 · 2017: 3 · 2016: 5 · 2015: 6 · 2014: 9 · 2013: 6 · 2012: 10
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- S-1, oral fluoropyrimidine, tegafur, 5-fluorouracil prodrug, dihydropyrimidine dehydrogenase inhibition, potassium oxonate, gastric cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, combination chemotherapy
- MeSH terms
- Administration, Oral, Animals, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Drug Combinations, Drug Evaluation, Preclinical, Tegafur, Humans, Neoplasms, Oxonic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.